Comment from American Academy of Pediatrics

Summary: The American Academy of Pediatrics (AAP) expresses general support for the FDA's pilot program to use AI in early-phase clinical trials, particularly to accelerate drug development for pediatric populations. They provide specific recommendations on trial design, collaboration models, and evaluation metrics, emphasizing the need for safety, health equity, and the preservation of ethical protections for children.